BioNTech settles Covid-19 patent dispute with CureVac, P4

By Coral Murphy Marcos

August 8, 2025

Source: The Guardian

Photo / Image Source: Unsplash,

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival.  Vaccine makers used messenger RNA, known as mRNA, to discover and develop the Covid-19 shots in record time during the pandemic.  But their success quickly descended into battles over who held the key patents on the novel technology, which teaches the body’s immune system to recognise part of the genetic code of the virus.   Under the new deal, GSK will receive $370mn upfront and 1 per cent of all US sales of the Covid-19, flu, and any combination vaccines from the start of 2025.  The payments are due to the UK-based drugmaker’s partnership to develop mRNA vaccines with CureVac, another German biotech, which BioNTech plans to acquire in an all-share deal that would give the company an enterprise value of about $900mn.  During the pandemic, GSK contributed its adjuvant — a technology that boosts the efficacy of some vaccines — to other vaccine makers’ shots, but did not develop its own. 

The Myth of Mental Illness: Foundations of a Theory of Personal Conduct

How can such practices impact your health? How Why?

COVID Vaccine. Shidonna Raven Garden & Cook, Soaring by Design

Fitness & Exercise

Subscribe

Share the wealth of health with your friends and family by sharing this article with 3 people today.

If this article was helpful to you, donate to the Shidonna Raven Garden and Cook E-Magazine Today. Thank you in advance.